Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Subscribe To Our Newsletter & Stay Updated
